Breaking into the Biologics and Biosimilars Market: Devising Forward-Thinking Portfolio Strategies

June 28, 2023 11:30am

Alicia A. Russo
Venable LLP

Hans Sauer, Ph.D., J.D.
Deputy General Counsel, VP of IP
Biotechnology Innovation Organization

Eamonn Gardner
Cooley LLP

  • Reviewing the biggest deals and acquisitions in the market place
  • Evaluating the clinical pipeline by company, indication and phase
    • Analyzing the market share for biosimilars in the U.S. and abroad
    • Target drugs with highest spending
    • Current market dynamics and considerations for biosimilar adoption
    • Utilizing historical biosimilar trends to provide potential future biosimilar spending and saving scenarios
  • Considering partnership agreements to offset capital costs and risk of biosimilar development and production